Top

Diabetologia

Published in:

01-07-2012 | Article

Delta cell secretory responses to insulin secretagogues are not mediated indirectly by insulin

Authors: A. C. Hauge-Evans, R. L. Anderson, S. J. Persaud, P. M. Jones

Published in: Diabetologia | Issue 7/2012

Abstract

Aims/hypothesis

Somatostatin from islet delta cells inhibits insulin and glucagon secretion, but knowledge of the regulation of pancreatic somatostatin release is limited. Some insulin secretagogues stimulate somatostatin secretion, and here we investigated whether delta cell secretory responses are indirectly regulated in a paracrine manner by insulin released from beta cells.

Methods

Hormone release from static incubations of primary mouse islets or somatostatin-secreting TGP52 cells was measured by RIA. mRNA expression was assessed by RT-PCR.

Results

Glucose and a range of other physiological and pharmacological agents stimulated insulin and somatostatin release, and insulin receptor mRNA was expressed in islets, MIN6 beta cells and TGP52 cells. However, exogenous insulin did not modulate basal or glucose-induced somatostatin secretion from islets, nor did pre-incubation with an antibody against the insulin receptor or with the insulin receptor tyrosine kinase inhibitor, HNMPA(AM)₃. Glucose and tolbutamide stimulated somatostatin release from TGP52 cells, whereas a range of receptor-operating agents had no effect, the latter being consistent with a lack of corresponding receptor mRNA expression in these cells. Parasympathetic activation stimulated insulin, but inhibited somatostatin release from mouse islets in accordance with differences in muscarinic receptor mRNA expression in islets, MIN6 and TGP52 cells. The inhibitory effect on somatostatin secretion was reversed by pertussis toxin or the muscarinic receptor 2 antagonist, methoctramine.

Conclusions/interpretations

A number of insulin secretagogues have analogous effects on insulin and somatostatin release, but this similarity of response is not mediated by an indirect, paracrine action of insulin on delta cells.

Available only for authorised users

Bosco D, Orci L, Meda P (1989) Homologous but not heterologous contact increases the insulin secretion of individual pancreatic B cells. Exp Cell Res 184:72–80PubMedCrossRef

Halban PA, Wollheim CB, Blondel B, Meda P, Niesor EN, Mintz DH (1982) The possible importance of contact between pancreatic islet cells for the control of insulin release. Endocrinology 111:86–94PubMedCrossRef

Hauge-Evans AC, Squires PE, Persaud SJ, Jones PM (1999) Pancreatic beta-cell-to-beta-cell interactions are required for integrated responses to nutrient stimuli: enhanced Ca2+ and insulin secretory responses of MIN6 pseudoislets. Diabetes 48:1402–1408PubMedCrossRef

Hopcroft DW, Mason DR, Scott RS (1985) Insulin secretion from perifused rat pancreatic pseudoislets. In Vitro Cell Dev Biol 21:421–427PubMedCrossRef

Luther MJ, Hauge-Evans A, Souza KL et al (2006) MIN6 beta-cell–beta-cell interactions influence insulin secretory responses to nutrients and non-nutrients. Biochem Biophys Res Commun 343:99–104PubMedCrossRef

Brereton H, Carvell MJ, Persaud SJ, Jones PM (2007) Islet alpha-cells do not influence insulin secretion from beta-cells through cell–cell contact. Endocrine 31:61–65PubMedCrossRef

Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB (2005) Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54:1808–1815PubMedCrossRef

Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB (2003) Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 5:330–335PubMedCrossRef

Ravier MA, Rutter GA (2005) Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 54:1789–1797PubMedCrossRef

10.

Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P (2011) Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab 13(Suppl 1):95–105PubMedCrossRef

11.

Hauge-Evans AC, King AJ, Carmignac D et al (2009) Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 58:403–411PubMedCrossRef

12.

Vieira E, Salehi A, Gylfe E (2007) Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia 50:370–379PubMedCrossRef

13.

Cejvan K, Coy DH, Holst JJ, Cerasi E, Efendic S (2002) Gliclazide directly inhibits arginine-induced glucagon release. Diabetes 51(Suppl 3):S381–S384PubMedCrossRef

14.

Sako Y, Wasada T, Umeda F, Ibayashi H (1986) Effect of glibenclamide on pancreatic hormone release from isolated perifused islets of normal and cysteamine-treated rats. Metabolism 35:944–949PubMedCrossRef

15.

Guenifi A, Ahren B, Abdel-Halim SM (2001) Differential effects of glucagon-like peptide-1 (7–36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. Pancreas 22:58–64PubMedCrossRef

16.

Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J (2003) Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol 469:195–200PubMedCrossRef

17.

D’Alessio DA, Fujimoto WY, Ensinck JW (1989) Effects of glucagon-like peptide I-(7–36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes 38:1534–1538PubMedCrossRef

18.

Fehmann HC, Hering BJ, Wolf MJ et al (1995) The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 11:196–200PubMedCrossRef

19.

Gros L, Thorens B, Bataille D, Kervran A (1993) Glucagon-like peptide-1-(7–36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 133:631–638PubMedCrossRef

20.

Heller RS, Aponte GW (1995) Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7–36) amide. Am J Physiol 269:G852–G860PubMed

21.

Muller D, Huang GC, Amiel S, Jones PM, Persaud SJ (2007) Gene expression heterogeneity in human islet endocrine cells in vitro: the insulin signalling cascade. Diabetologia 50:1239–1242PubMedCrossRef

22.

Murakami K, Taniguchi H, Tamagawa M, Ejiri K, Baba S (1982) Modulation of somatostatin release by endogenous glucagon and insulin: physiological relationship between A, B and D cells in rat pancreatic islets. Endocrinol Jpn 29:503–508PubMedCrossRef

23.

Patton GS, Ipp E, Dobbs RE, Orci L, Vale W, Unger RH (1977) Pancreatic immunoreactive somatostatin release. Proc Natl Acad Sci USA 74:2140–2143PubMedCrossRef

24.

Stagner J, Samols E, Polonsky K, Pugh W (1986) Lack of direct inhibition of insulin secretion by exogenous insulin in the canine pancreas. J Clin Invest 78:1193–1198PubMedCrossRef

25.

Brunicardi FC, Kleinman R, Moldovan S et al (2001) Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas. Pancreas 23:302–308PubMedCrossRef

26.

Trimble ER, Gerber PP, Renold AE (1981) Abnormalities of pancreatic somatostatin secretion corrected by in vivo insulin treatment of streptozotocin-diabetic rats. Diabetes 30:865–867PubMedCrossRef

27.

Gey GO, Gey MK (2008) Maintenance of human normal cells in continuous culture, preliminary report: cultivation of mesoblastic tumours and normal cells and notes on methods of cultivation. Am J Cancer 27:45–76

28.

Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRef

29.

Hauge-Evans AC, Squires PE, Belin VD et al (2002) Role of adenine nucleotides in insulin secretion from MIN6 pseudoislets. Mol Cell Endocrinol 191:167–176PubMedCrossRef

30.

Gromada J, Holst JJ, Rorsman P (1998) Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 435:583–594PubMedCrossRef

31.

Lobner K, Steinbrenner H, Roberts GA et al (2002) Different regulated expression of the tyrosine phosphatase-like proteins IA-2 and phogrin by glucose and insulin in pancreatic islets: relationship to development of insulin secretory responses in early life. Diabetes 51:2982–2988PubMedCrossRef

32.

Muller D, Jones PM, Persaud SJ (2006) Autocrine anti-apoptotic and proliferative effects of insulin in pancreatic beta-cells. FEBS Lett 580:6977–6980PubMedCrossRef

33.

Gilon P, Henquin JC (2001) Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev 22:565–604PubMedCrossRef

34.

Persaud SJ, Jones PM, Howell SL (1989) Effects of Bordetella pertussis toxin on catecholamine inhibition of insulin release from intact and electrically permeabilized rat islets. Biochem J 258:669–675PubMed

35.

Cejvan K, Coy DH, Efendic S (2003) Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 52:1176–1181PubMedCrossRef

36.

Utsumi M, Makimura H, Ishihara K, Morita S, Baba S (1979) Determination of immunoreactive somatostatin in rat plasma and responses to arginine, glucose and glucagon infusion. Diabetologia 17:319–323PubMedCrossRef

37.

Hellman B (2009) Pulsatility of insulin release—a clinically important phenomenon. Ups J Med Sci 114:193–205PubMedCrossRef

38.

Hoy M, Olsen HL, Bokvist K, Petersen JS, Gromada J (2003) The imidazoline NNC77-0020 affects glucose-dependent insulin, glucagon and somatostatin secretion in mouse pancreatic islets. Naunyn Schmiedebergs Arch Pharmacol 368:284–293PubMedCrossRef

39.

Obermuller S, Calegari F, King A et al (2010) Defective secretion of islet hormones in chromogranin-B deficient mice. PLoS One 5:e8936PubMedCrossRef

40.

Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A (2006) The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 103:2334–2339PubMedCrossRef

41.

Schaffer L, Brand CL, Hansen BF et al (2008) A novel high-affinity peptide antagonist to the insulin receptor. Biochem Biophys Res Commun 376:380–383PubMedCrossRef

42.

Persaud SJ, Asare-Anane H, Jones PM (2002) Insulin receptor activation inhibits insulin secretion from human islets of Langerhans. FEBS Lett 510:225–228PubMedCrossRef

43.

Persaud SJ (1999) Pancreatic beta-cell lines: their roles in beta-cell research and diabetes therapy. Adv Mol Cell Biol 29:21–46CrossRef

44.

Gopel SO, Kanno T, Barg S, Rorsman P (2000) Patch-clamp characterisation of somatostatin-secreting-cells in intact mouse pancreatic islets. J Physiol 528:497–507PubMedCrossRef

45.

Quesada I, Todorova MG, Soria B (2006) Different metabolic responses in alpha-, beta-, and delta-cells of the islet of Langerhans monitored by redox confocal microscopy. Biophys J 90:2641–2650PubMedCrossRef

46.

Berts A, Ball A, Dryselius G, Gylfe E, Hellman B (1996) Glucose stimulation of somatostatin-producing islet cells involves oscillatory Ca2+ signaling. Endocrinology 137:693–697PubMedCrossRef

47.

Hermansen K, Christensen SE, Orskov H (1979) Characterization of somatostatin release from the pancreas: the role of potassium. Scand J Clin Lab Invest 39:717–722PubMedCrossRef

48.

Hermansen K, Christensen SE, Orskov H (1979) Characterisation of somatostatin release from the pancreas: the role of calcium and acetylcholine. Diabetologia 16:261–266PubMedCrossRef

49.

Zhang Q, Bengtsson M, Partridge C et al (2007) R-type Ca(2+)-channel-evoked CICR regulates glucose-induced somatostatin secretion. Nat Cell Biol 9:453–460PubMedCrossRef

50.

Heller RS, Kieffer TJ, Habener JF (1997) Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46:785–791PubMedCrossRef

51.

Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS (2008) Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56:841–851PubMedCrossRef

52.

Moens K, Heimberg H, Flamez D et al (1996) Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45:257–261PubMedCrossRef

53.

Kieffer TJ, Heller RS, Unson CG, Weir GC, Habener JF (1996) Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137:5119–5125PubMedCrossRef

54.

Itoh M, Gerich JE (1982) Adrenergic modulation of pancreatic somatostatin, insulin, and glucagon secretion: evidence for differential sensitivity of islet A, B, and D cells. Metabolism 31:715–720PubMedCrossRef

55.

Samols E, Weir GC (1979) Adrenergic modulation of pancreatic A, B, and D cells alpha-adrenergic suppression and beta-adrenergic stimulation of somatostatin secretion, alpha-adrenergic stimulation of glucagon secretion in the perfused dog pancreas. J Clin Invest 63:230–238PubMedCrossRef

56.

Gagerman E, Idahl LA, Meissner HP, Taljedal IB (1978) Insulin release, cGMP, cAMP, and membrane potential in acetylcholine-stimulated islets. Am J Physiol 235:E493–E500PubMed

57.

Dunlop ME, Larkins RG (1986) Muscarinic-agonist and guanine nucleotide activation of polyphosphoinositide phosphodiesterase in isolated islet-cell membranes. Biochem J 240:731–737PubMed

Title: Delta cell secretory responses to insulin secretagogues are not mediated indirectly by insulin
Authors: A. C. Hauge-Evans
R. L. Anderson
S. J. Persaud
P. M. Jones
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 7/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-012-2546-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Delta cell secretory responses to insulin secretagogues are not mediated indirectly by insulin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretations

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretations

Please log in to get access to this content

Other articles of this Issue 7/2012

Zinc transporter (ZnT)8186–194 is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes

Chronic kidney disease categories and renal–cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25)

Worth the wait: type 1 diabetes prospective birth cohort studies enter adolescence

Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page